Ascentage Pharma Group International (AAPG) Equity Average (2023 - 2024)
Ascentage Pharma Group International posted quarterly Equity Average of $23.3 million for Q4 2024, down 30.74% year-on-year from $33.6 million in Q1 2024, and down 30.74% on a QoQ basis from $33.6 million in Q4 2023.
Ascentage Pharma Group International (AAPG) has 2 years of Equity Average data on file, last reported at $23.3 million in Q4 2024.
- For the quarter ending Q4 2024, Equity Average fell 30.74% year-over-year to $23.3 million; the trailing twelve-month figure through Dec 2024 stood at $23.3 million (down 30.74% YoY), and the FY2025 full-year result was $94.7 million, up 1825.27% from the prior year.
- Equity Average for Q4 2024 stood at $23.3 million, down from $33.6 million in the prior quarter.
- Across five years, Equity Average topped out at $33.6 million in Q4 2023 and bottomed at $23.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 31.34 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Ascentage Pharma Group International | 1.11 Bn | 937.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 23.29 Mn |
| Dec 31, 2023 | 33.63 Mn |